From Fast Follower to First-in-Class Innovator: China’s 2015–2025 Drug Revolution

Introduction: A Decade Transformed (2015–2025)

In just ten years, China’s biopharma industry has evolved from a fast follower into a first-in-class innovator. Once trailing global leaders by more than a decade, China now leads in novel drug development. By 2024, the country advanced over 700 self-originated drug candidates, surpassing the U.S. in both pipeline size and ambition.¹,²

1. Policy Support: A Structural Transformation

China’s ascent is underpinned by sequential reforms that reshaped the industry. Regulatory modernization has been a critical driver, fostering an environment where innovation, rather than imitation, is rewarded.²,³

2015–2017: Regulatory Reset
The “7.22” clinical data cleanup and Document No. 44 aligned new drug standards with international norms, ending the era of me-too approvals.¹

2018–2020: Innovation Over Sales
The “4+7” procurement reform redirected incentives toward R&D, while updated registration rules enabled accelerated pathways for innovative drugs.¹,⁴

2021–2023: Smarter Competition
Clinical value–oriented R&D guidelines and accelerated review pilots, combined with anti-corruption campaigns, freed capital for true innovation.¹,⁵

2024–2025: Innovation as Strategy
National planning elevated innovation to a central role. Full-chain support plans, expanded insurance coverage, and tiered pricing reforms created long-term confidence for breakthrough therapies.¹,⁶

2. From Imitator to Innovator: Pipeline Acceleration

Rising Quality & First-in-Class (FIC) Innovation
In 2015, Chinese firms had only 9 self-originated FIC candidates in clinical development (<10% of the global total).²
By 2024, this number had surged to 120, representing 24% of the global FIC pipeline.²

Global Leadership in New Clinical Entries
Since 2020, China has consistently ranked #1 globally in the number of self-originated innovative drugs entering clinical trials each year.²
In 2024 alone, China advanced 704 new candidates, compared with U.S.: ~400–500; Europe: ~200; Japan: <100.²

Cumulative Pipeline Stock
From 2015–2024, Chinese firms accumulated 3,575 active innovative drugs in clinical development — more than any other country: U.S.: 2,967; South Korea: 390; Japan: 341; U.K.: 271.²

Dominance in Hot-Target Pipelines
By mid-2025, Chinese companies accounted for 68.4% of global clinical activity across major hot targets (EGFR, HER2, VEGF, IL-17, CD19, CLDN18.2, GLP-1).²,³

Shrinking Launch Gap
Time lags between global and Chinese launches have narrowed dramatically, from 8–18 years pre-2015 to under 2 years today, with some therapies now debuting first in China.²

The Shrinking Approval Gap

The Shrinking Approval Gap

3. Infrastructure Advantage & Research Momentum

China’s innovation is driven by a combination of industrial capability and a rapidly expanding scientific base:

Robust Basic Research
From 2015–2020, China’s biomedical publications grew at a 14.3% CAGR, reaching nearly 290,000 papers in 2020 — second only to the U.S.¹,⁷

Manufacturing & R&D Ecosystem
Leadership in peptides, ADCs, nucleotides, and cold-chain logistics supports rapid drug development.¹,⁸
CXO platforms (e.g., WuXi AppTec) enable global-standard R&D at scale.⁸

China’s Engineer Dividend

• Scale: In 2020, China had ~1M scientists and engineers, 2.6× the U.S. (300–400K).
• STEM graduates: By 2025, China produces 77,000 STEM graduates annually (bachelor’s, master’s, PhD), nearly double the U.S. (40,000).
• Cost efficiency: Pharma engineers in China earn ¥150–250K/year (~$20–35K), just 1/4–1/5 of U.S. levels ($100–140K).
• Youth advantage: A younger workforce increases long-term R&D productivity.

4. Global Validation: High-Value Deals
China’s outbound licensing and acquisitions underscore international confidence in its innovation.³

Bispecifics and ADCs dominate, underscoring China’s leap into first-in-class immunotherapies.

5. Case Study: BNT327 (Pumitamig)

From $55M to $1.5B upfront in 18 months, BNT327 exemplifies rapid value creation.³

Clinical Highlights³:

• SCLC (1L, global Phase II): ORR up to 100% (20 mg/kg cohort), DCR 100%
• Mesothelioma: cORR 51.6%, strong activity in peritoneal subtype
• TNBC: ORR 78.6%, PFS 13.5 months
• EGFR+ NSCLC (post-TKI): ORR 54.7%, up to 92.3% with high PD-L1 expression

BNT327’s trajectory illustrates China’s transition from follower to global innovation leader.

6. Global Trials & Market Presence

Chinese firms now run 2,000+ clinical trials per year, with ~5% international multicenter.³
By mid-2025, China accounts for 68% of global clinical activity across key hot targets.²,³
As of 2024, 18 China-origin innovative drugs have gained approvals in the U.S. and EU.³

Market Footprint: BeiGene’s zanubrutinib reached $800M in Q1 2025 U.S. sales, capturing #1 BTK market share.²

7. Domestic Transformation

Priority review & breakthrough designations cut ~200 days from timelines.¹
NDRL access: 90% of innovative drugs enter within two years of launch.¹
Market share: China-origin drugs rose from 18.7% (2015) → 27.8% (2024), led by oncology and immunology.²

Conclusion: China Now Shapes Global Pharma

China has moved from followership to leadership in a decade. Landmark assets like BNT327, alongside a maturing ecosystem, a surging research base, and billion-dollar partnerships, signal that China is now a pillar of global drug innovation—not just a participant.¹–¹³

References

1. Wang, L.; Sun, Y.; Huang, M. Current Landscape of Innovative Drug Development and Regulatory Reforms in China (2019–2023). Signal Transduct. Target. Ther. 2025, 10, 122.
2. Liu, S.; Hu, H.; Ge, C.; Yuan, S.; Jiang, J.; Chen, X. The Rise of China’s Pharmaceutical Industry from 2015–2024: A Decade of Innovation. Nat. Rev. Drug Discov. 2025, 24, 45–58.
3. Chen, J.; Liu, P.; Zhao, Q. Development of Chinese Innovative Drugs in the USA: Trends and Opportunities. Nat. Rev. Drug Discov. 2024, 23, 920–935.
4. China Pharmaceutical Innovation and Research Development Association; R&D-based Pharmaceutical Association Committee. Building China’s Pharmaceutical Innovation Ecosystem – Part One of the Series Research Reports: 2015–2020 Development Review and Future Prospects. April 2021.
5. Information Technology and Innovation Foundation. How Innovative Is China in Biotechnology? July 30, 2024.
6. Information Technology and Innovation Foundation. China Is Rapidly Becoming a Leading Innovator in Advanced Industries. September 16, 2024.
7. Porsche Consulting. China's Rise in Biopharma. 2024.
8. McKinsey & Company. The Dawn of China Biopharma Innovation. 2024.
9. ARC Group. China Innovative Pharma Going Global. 2024.
10. Carnegie Endowment for International Peace. Biopharmaceuticals Rising: China’s Strategic Pivot to Southeast Asia Amid Great Power Tech Competition. January 23, 2025.
11. Futu News. Institutions: Chinese Innovative Drugs Are Booming, but How Far Are They? June 2025.
12. ClinRegs. Clinical Research Regulation for China. 2024.
13. PubMed Central. Insights into Clinical Trials and Regulatory Advances in China. 2024.
14. PubMed Central. Clinical Development of CAR T Cell Therapy in China: 2020 Update. 2020.
15. Astellas Newsroom. China's National Medical Products Administration (NMPA) Approves VYLOY™ (Zolbetuximab) for First-Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. January 5, 2025.
16. Sanofi Press Release. Dupixent Approved in China as the First-Ever Biologic Medicine for Patients with COPD. September 27, 2024.
17. Innovent Biologics. Healthy China 2030 Oncology Summit & Innovent Biologics R&D Day. August 2025.
18. Greenberg Traurig. Lessons from China's 2024 National Negotiation of Drug Prices. February 2025.
19. The Times. GSK Deepens Its Ties to China with $500M Hengrui Pharma Deal. July 2025.
20. Axios. China's Biotech Boom Leaves U.S. Playing Catch-Up. May 29, 2025.
21. The Wall Street Journal. The Drug Industry Is Having Its Own DeepSeek Moment. January 2025.
22. New York Post. China's Lapping Us in Biotech - But Here's How We Can Fight Back. April 11, 2025.
23. Financial Times. Rapid Trials Prompt Deals Rush for Chinese 'Super Me-Too' Drugs. June 2025.
24. San Francisco Chronicle. The U.S. Is Losing Its Biotech Edge Over China - and That's Bad News for the Bay Area. May 2025.
25. Bloomberg. China Biotech's Stunning Advance Is Changing the World's Drug Development Landscape. July 13, 2025.